Korro Bio (KRRO) major holder adds stock and pre-funded warrants in March 2026 buy
Rhea-AI Filing Summary
Korro Bio, Inc. reported that an entity associated with major holder Edward T. Mathers bought additional securities. On March 10, 2026, New Enterprise Associates 17, L.P., for which Mathers is an affiliated manager, acquired 242,945 Pre-Funded Warrants at $11.109 per underlying share and 207,100 shares of Common Stock at $11.110 per share in a purchase coded as an open-market transaction and documented in a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per share but contain a Beneficial Ownership Limitation that generally caps the holder’s ownership at 9.99% of Korro Bio’s outstanding Common Stock after exercise, with the cap adjustable on 61 days’ notice up to 19.99%. Following these transactions, indirect holdings reported for Common Stock totaled 1,297,893 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Pre-Funded Warrants | 242,945 | $11.109 | $2.70M |
| Purchase | Common Stock | 207,100 | $11.11 | $2.30M |
Footnotes (1)
- Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.